低剂量利多卡因对颈椎板间硬膜外注射后上肢肌力及即刻疼痛缓解的影响:双盲随机对照试验
该双盲随机对照试验纳入120例颈椎神经根性疼痛行颈椎板间硬膜外类固醇注射(CIESI)的患者,比较利多卡因与生理盐水作为稀释剂的效果。结果显示,两组注射后肌节无力(≥20% MCID)比例无显著差异(利多卡因组41.7% vs 盐水组50%),疼痛缓解率也无显著差异(相对风险1.53,95%CI 0.82-2.86)。结论认为低剂量利多卡因不显著增加无力风险,也未显著提高即刻疼痛缓解的可能性。
要点
- 低剂量利多卡因作为CIESI稀释剂不显著增加注射后肌节无力风险。
- 利多卡因与盐水相比未显著提高即刻疼痛缓解率(RR 1.53,95%CI 0.82-2.86)。
- 研究中无力定义为≥20% MCID且累及>1个肌节,两组发生率无显著差异。
核心结论
- 低剂量利多卡因作为CIESI稀释剂不显著增加注射后肌节无力风险,但也未显著提高即刻有临床意义的疼痛缓解可能性。
研究设计与样本
- 双盲随机对照试验,纳入120例因颈椎神经根性疼痛行CIESI的患者,随机接受利多卡因(CIESI-L,n=60)或生理盐水(CIESI-S,n=60)作为硬膜外注射液的稀释剂。
主要发现
- 注射后无力(≥20% MCID且>1个肌节)比例:利多卡因组41.7%(95%CI 29.8%-54.5%),盐水组50%(95%CI 37.5%-62.5%),组间无显著差异。
- 疼痛缓解(数值量表评分降低≥50%)的组间比较相对风险为1.53(95%CI 0.82-2.86),无显著差异。
关键数值与推荐
- 主要结局为注射后>1个肌节出现≥20%无力(MCID)。
- 次要结局为数值量表疼痛评分降低≥50%。
临床怎么用
- CIESI中使用低剂量利多卡因作为稀释剂未显著增加上肢无力风险,但也不应期望其能显著提高即刻疼痛缓解率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Low-dose lidocaine is a common diluent for analgesia following cervical interlaminar epidural steroid injection (CIESI). Concerns with this practice exist. A single-arm cohort reported that 20% of patients develop postprocedural upper extremity weakness when using lidocaine as a diluent. Furthermore, a high-cervical spinal block with unintended intrathecal or subdural administration is possible. OBJECTIVE: Determine if low-dose lidocaine as a diluent during CIESI causes clinically meaningful (1) upper extremity weakness and (2) immediate pain relief when compared with saline. DESIGN: Double-blinded randomized control trial. METHODS: Patients with cervical radicular pain scheduled for CIESI were enrolled. Participants received lidocaine (CIESI-L) or saline (CIESI-S) as a diluent for the epidural injectate. Myotomal strength was measured with dynamometry before and between 20 and 30 min after CIESI. Pre-pain and post-pain scores were obtained. Primary and secondary outcomes were post-CIESI weakness of ≥20% (minimal clinically important difference (MCID)) in >1 myotome and ≥50% pain reduction on the numerical scale. RESULTS: 120 participants (64 females (53%), mean age, 56 (SD 13.7) years) completed the study and were analyzed (CIESI-L n=60; CIESI-S n=60). There was no significant between-group difference in the proportion of participants with postprocedural weakness, CIESI-L 41.7% (95% CI, 29.8% to 54.5%), CIESL-S 50% (95% CI, 37.5% to 62.5%). Between-group comparison showed no significant difference in pain reduction, relative risk 1.53 (95% CI, 0.82 to 2.86). CONCLUSION: Low-dose lidocaine as a diluent in CIESI does not significantly increase the risk of post-CIESI myotomal weakness when compared with saline, but also does not substantially increase the likelihood of immediate, meaningful pain relief. TRIAL REGISTRATION DETAILS: ClinicalTrials.gov (NCT03127137); December 26, 2017.
引用
- McCormick ZL, Burnham T, Cunningham S, et al. Effect of low-dose lidocaine on objective upper extremity strength and immediate pain relief following cervical interlaminar epidural injections: a double-blinded randomized controlled trial. Reg Anesth Pain Med. 2020. PMID: 32784231. doi:10.1136/rapm-2020-101598
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。